Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Trial details
- Registry ID
- NCT07154706
- Drugs studied
- Taletrectinib
TrialRedline tracks 7 clinical trials sponsored by Nuvation Bio Inc.: 3 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706 | Taletrectinib | Recruiting | 2030-08-30Estimated |
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsNCT06564324 | Crizotinib, Taletrectinib | Recruiting | 2029-01Estimated |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)NCT05303519 | safusidenib | Recruiting | 2028-12-01Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseNCT07703436 | Safusidenib | Recruiting | 2030-09Estimated |
| Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCNCT04919811 | Taletrectinib | Active not recruiting | 2025-06-11Actual |
| A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneNCT04395677 | AB-106 | Active not recruiting | 2024-06-07Actual |
| Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionNCT04617054 | AB-106 | Terminated | 2024-12-06Actual |
Names as written in the registry records.
Before: Not yet recruiting. After: Recruiting.
Before: 138 participants (planned). After: 194 participants (planned).
NCT04395677 · Nuvation Bio Inc.
Before: Estimated. After: Actual.
Before: Estimated. After: Actual.
Before: 30 Dec 2023. After: 7 Jun 2024.
NCT05303519 · Nuvation Bio Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0. After: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 Measure: Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0.
Before: 125 participants (planned). After: 365 participants (planned).
Before: 1 Dec 2027. After: 1 Dec 2028.
Before: PHASE2. After: PHASE3.
NCT04617054 · Nuvation Bio Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Best overall response (BOR). After: Measure: Objective response rate (ORR).
Before: Estimated. After: Actual.
Before: 40 participants (planned). After: 14 participants (actual).
Before: Estimated. After: Actual.
Before: 30 Apr 2024. After: 6 Dec 2024.
Before: Recruiting. After: Terminated.